Health & Medicine · Cardiology · Cardiovascular Risk
HAS-BLED Score Calculator
Calculates the HAS-BLED score to estimate 1-year risk of major bleeding in patients with atrial fibrillation on anticoagulation therapy.
Calculator
Formula
Each letter represents a clinical risk factor scored 0 or 1 (except Abnormal renal/liver function and Bleeding history/predisposition, which can each contribute up to 2 points): H = Hypertension (uncontrolled, SBP >160 mmHg); A = Abnormal renal function (1 pt) and/or Abnormal liver function (1 pt); S = Stroke history; B = Bleeding history or predisposition; L = Labile INR (time in therapeutic range <60%); E = Elderly (age >65); D = Drugs (antiplatelet agents or NSAIDs, 1 pt) and/or Alcohol use (1 pt). Maximum total score is 9.
Source: Pisters R, et al. A Novel User-Friendly Score (HAS-BLED) to Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation. Chest. 2010;138(5):1093–1100.
How it works
The HAS-BLED score assigns one point for each of nine modifiable and non-modifiable clinical risk factors associated with major bleeding. The acronym stands for: Hypertension, Abnormal renal or liver function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly (age >65), and Drugs (antiplatelets or NSAIDs) or alcohol use. Because both 'A' and 'D' can each contribute up to 2 points, the maximum possible score is 9.
The total score correlates with an estimated annual rate of major bleeding events per 100 patient-years. Scores of 0–1 indicate low risk (~1.0–1.1%/year), a score of 2 indicates moderate risk (~1.88%/year), and scores of 3 or above signal high risk (≥3.74%/year), with scores ≥5 carrying a rate exceeding 12%/year. Importantly, a high HAS-BLED score does not automatically contraindicate anticoagulation; rather, it prompts clinicians to identify and address correctable risk factors.
The score is best used alongside the CHA₂DS₂-VASc score, which estimates stroke risk. When the stroke risk substantially outweighs bleeding risk, anticoagulation is typically initiated. The HAS-BLED framework also highlights modifiable factors — such as uncontrolled hypertension, labile INR, concurrent NSAID use, or excessive alcohol consumption — that can be actively addressed to reduce a patient's bleeding risk while maintaining anticoagulation benefit.
Worked example
Clinical scenario: A 72-year-old male with atrial fibrillation is being evaluated for warfarin therapy. His clinical details are as follows:
- Blood pressure: 168/92 mmHg (uncontrolled) → H = 1
- eGFR: 58 mL/min, no dialysis or transplant → Abnormal renal = 0
- No liver disease, normal bilirubin and transaminases → Abnormal liver = 0
- Prior ischemic stroke 3 years ago → S = 1
- No prior bleeding episodes, no known coagulopathy → B = 0
- Time in therapeutic INR range (TTR): 48% → L = 1
- Age 72 → E = 1
- On low-dose aspirin for secondary prevention → D (drugs) = 1
- Drinks 2 units of alcohol per week → D (alcohol) = 0
Total HAS-BLED score = 1 + 0 + 0 + 1 + 0 + 1 + 1 + 1 + 0 = 5 points
A score of 5 places this patient in the high-risk category with an estimated annual major bleeding rate of approximately 12.5%. However, the modifiable risk factors — uncontrolled hypertension, labile INR, and concurrent aspirin use — should be actively addressed. His CHA₂DS₂-VASc score would also be calculated to weigh the stroke benefit, and a shared decision-making discussion about anticoagulation would be appropriate.
Limitations & notes
The HAS-BLED score was originally derived and validated in European cohorts of anticoagulated AFib patients and may not perfectly generalize to all populations or anticoagulant types. The score was developed primarily in the context of vitamin K antagonist (warfarin) therapy; its performance with direct oral anticoagulants (DOACs) is still being studied, though it is widely applied across anticoagulant classes. A high HAS-BLED score should never be interpreted as a definitive contraindication to anticoagulation — it is a risk stratification tool, not a prescribing directive. The labile INR component applies only to patients on warfarin and cannot be calculated for DOAC users or anticoagulation-naive patients. Some components, such as 'bleeding predisposition,' require clinical judgment and may be inconsistently applied. Additionally, the score does not account for the dynamic nature of bleeding risk, which may change as clinical conditions evolve over time. Always integrate HAS-BLED results with CHA₂DS₂-VASc, individual patient preferences, fall risk, comorbidities, and multidisciplinary clinical judgment.
Frequently asked questions
What HAS-BLED score is considered high risk for bleeding?
A HAS-BLED score of 3 or higher is generally considered high risk, with an annual major bleeding rate of approximately 3.74% or greater. Scores of 5 or above are associated with bleeding rates exceeding 12% per year and warrant particularly careful clinical evaluation before initiating or continuing anticoagulation.
Does a high HAS-BLED score mean I should stop anticoagulation?
Not necessarily. A high HAS-BLED score signals that modifiable bleeding risk factors should be identified and corrected — such as controlling blood pressure, improving INR stability, or discontinuing NSAIDs. It should be weighed against the patient's stroke risk (CHA₂DS₂-VASc score); in many cases, anticoagulation still provides a net clinical benefit even when HAS-BLED is elevated.
Can HAS-BLED be used for patients on DOACs instead of warfarin?
HAS-BLED was originally developed and validated in patients on vitamin K antagonists such as warfarin. The labile INR component (L) is not directly applicable to DOAC users. Despite this limitation, the score is still widely used as a bleeding risk guide in clinical practice for DOAC-treated patients, with the L component typically scored as 0.
What is the difference between HAS-BLED and CHA₂DS₂-VASc?
HAS-BLED estimates the risk of major bleeding, while CHA₂DS₂-VASc estimates the risk of thromboembolic stroke. Both scores are used together in the management of atrial fibrillation. When stroke risk (CHA₂DS₂-VASc) significantly exceeds bleeding risk (HAS-BLED), anticoagulation is generally recommended. They complement rather than replace each other in clinical decision-making.
Which HAS-BLED risk factors can be modified to reduce bleeding risk?
Several HAS-BLED components are potentially modifiable: uncontrolled hypertension (H) can be treated with antihypertensives; labile INR (L) can be improved with better warfarin management or by switching to a DOAC; concurrent antiplatelet or NSAID use (D) can often be discontinued or substituted; and excessive alcohol consumption (D) can be addressed through counseling and behavioral intervention. Targeting these factors can meaningfully lower a patient's overall bleeding risk.
Last updated: 2025-01-15 · Formula verified against primary sources.